0
Signin
countryflagUS

18889881171

AAPL 169.38 0.213% MSFT 395.01 -3.4347% GOOG 157.28 -2.3712% GOOGL 155.62 -2.2057% AMZN 172.26 -2.452% NVDA 822.64 3.2469% META 437.68 -11.311% TSLA 164.345 1.3662% TSM 136.66 2.7751% LLY 726.29 -0.8072% V 274.6 -0.1527% AVGO 1296.3043 3.1416% JPM 193.3 0.1139% UNH 494.74 1.5268% NVO 125.02 -0.9036% WMT 60.51 1.069% LVMUY 167.4155 -2.4499% XOM 120.83 -0.1817% LVMHF 839.31 -2.3774% MA 461.62 -0.1903%

Moderna Inc

Healthcare US MRNA

105.25USD
-3.6(3.31%)

Last update at 2024-04-25T16:49:00Z

Day Range

103.52108.23
LowHigh

52 Week Range

62.55207.51
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 9575.00M 13285.00M -744.51300M -514.71600M -384.40800M
Minority interest - - - - -
Net income 8362.00M 12202.00M -747.06400M -514.02100M -384.73400M
Selling general administrative 1132.00M 567.00M 188.27M 109.62M 94.25M
Selling and marketing expenses - - - - -
Gross profit 13847.00M 15119.00M 266.56M 48.04M 135.07M
Reconciled depreciation 348.00M 232.00M 31.25M 31.02M 24.86M
Ebit 9420.00M 13064.00M -794.39500M -576.74100M -438.12800M
Ebitda 9768.00M 13296.00M -763.14400M -545.72000M -413.26600M
Depreciation and amortization 348.00M 232.00M 31.25M 31.02M 24.86M
Non operating income net other 155.00M -11.00000M 18.63M 31.00M 28.86M
Operating income 9420.00M 13296.00M -763.14400M -545.72000M -413.26600M
Other operating expenses 9843.00M 4440.00M 1037.63M 593.76M 535.78M
Interest expense 29.00M 18.00M 9.89M 6.61M 0.00000M
Tax provision 1213.00M 1083.00M 2.55M -0.69500M 0.33M
Interest income 200.00M 18.00M 24.71M 38.53M 27.02M
Net interest income 200.00M 18.00M 14.83M 31.92M 27.02M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 1213.00M 1083.00M 2.55M -0.69500M 0.33M
Total revenue 19263.00M 17736.00M 274.49M 48.04M 122.51M
Total operating expenses 4427.00M 1823.00M 1029.70M 593.76M 535.78M
Cost of revenue 5416.00M 2617.00M 7.93M 496.31M -12.55600M
Total other income expense net 155.00M -11.00000M 18.63M 31.00M 1.83M
Discontinued operations - - - - -
Net income from continuing ops 8362.00M 12202.00M -747.06400M -514.02100M -384.73400M
Net income applicable to common shares 8362.00M 12202.00M -747.06400M -514.02100M -401.85700M
Preferred stock and other adjustments - - - - 17.12M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 25858.00M 24669.00M 7336.75M 1589.42M 1962.15M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 1195.00M 55.00M -405.63100M 887.90M 11.00M
Total liab 6735.00M 10524.00M 4775.38M 414.61M 431.91M
Total stockholder equity 19123.00M 14145.00M 2561.38M 1174.81M 1530.24M
Deferred long term liab - - - - -
Other current liab 2202.00M 2362.00M 33.66M 5.06M 3.46M
Common stock - -857.00000M 0.04M 0.03M 0.03M
Capital stock 0.00000M 0.00000M 0.04M 0.03M 0.03M
Retained earnings 18320.00M 9958.00M -2243.51800M -1496.45400M -1006.62700M
Other liab 808.00M 691.00M 179.27M 139.13M 175.62M
Good will - - - - -
Other assets 1928.00M 7383.00M 741.98M 12.72M 14.18M
Cash 3205.00M 6848.00M 2623.85M 235.88M 658.36M
Cash and equivalents - - - - -
Total current liabilities 4923.00M 9128.00M 4388.81M 143.12M 222.80M
Current deferred revenue 2038.00M 6253.00M 3867.19M 63.31M 109.06M
Net debt -2005.00000M -5932.00000M -2416.55500M -103.51200M -624.87500M
Short term debt 196.00M 211.00M 469.59M 67.65M 79.07M
Short long term debt - - - - -
Short long term debt total 1200.00M 916.00M 207.29M 132.36M 33.49M
Other stockholder equity 1173.00M 4211.00M 4801.85M 2669.43M 576.01M
Property plant equipment 2139.00M 1383.00M 387.09M 287.91M 211.98M
Total current assets 13431.00M 17570.00M 6297.88M 1262.99M 1563.01M
Long term investments 8318.00M 6843.00M 638.85M 159.99M 172.99M
Net tangible assets 19123.00M 14145.00M 2561.38M 1174.81M 1530.24M
Short term investments 6697.00M 3879.00M 1983.76M 867.12M 863.06M
Net receivables 1385.00M 3296.00M 1410.53M 16.30M 30.58M
Long term debt - - - - -
Inventory 949.00M 1441.00M 46.53M -904.19300M -172.99000M
Accounts payable 487.00M 302.00M 18.36M 7.09M 31.21M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -370.00000M -24.00000M 3.00M 1.80M -1.32000M
Additional paid in capital - - - - -
Common stock total equity - - 0.04M 0.03M 0.03M
Preferred stock total equity - - - - -
Retained earnings total equity 18320.00M 9958.00M -2243.51800M -1500.00000M -1006.62700M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 988.00M 46.00M 12.93M -121.46100M 14.18M
Deferred long term asset charges - - - - -
Non current assets total 12427.00M 7099.00M 1038.87M 326.44M 399.14M
Capital lease obligations 1004.00M 916.00M 207.29M 132.36M 33.49M
Long term debt total - - - 38.69M 33.49M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -5176.00000M -8239.00000M -1604.48000M 16.61M -267.32800M
Change to liabilities 112.00M 2192.00M 406.26M -77.61400M -40.54600M
Total cashflows from investing activities -5176.00000M -8523.00000M -1671.92800M -14.94500M -372.47200M
Net borrowings -184.00000M -140.00000M -6.21500M 0.97M 9.46M
Total cash from financing activities -3448.00000M -873.00000M 2033.19M 51.12M 1226.84M
Change to operating activities -992.00000M 582.00M 154.59M 7.20M 6.83M
Net income 8362.00M 12202.00M -747.06400M -514.02100M -384.73400M
Change in cash -3643.00000M 4224.00M 2388.24M -422.79200M 523.50M
Begin period cash flow 6860.00M 2636.00M 247.70M 670.49M 134.86M
End period cash flow 3217.00M 6860.00M 2635.93M 247.70M 658.36M
Total cash from operating activities 4981.00M 13620.00M 2026.97M -458.96800M -330.86500M
Issuance of capital stock 0.00000M 0.00000M 1852.72M 0.00000M 1224.14M
Depreciation 348.00M 232.00M 31.25M 31.02M 24.86M
Other cashflows from investing activities -40.00000M -30.00000M -30.00000M 16.61M 0.62M
Dividends paid - -124.00000M -7.04000M - -
Change to inventory 492.00M -1394.00000M -46.52700M 7.20M 4.41M
Change to account receivables 1790.00M -1784.00000M -1385.19100M 7.22M 0.83M
Sale purchase of stock -3329.00000M -857.00000M 7.04M 2.89M -8.18200M
Other cashflows from financing activities -184.00000M 124.00M 186.68M 0.97M 674.17M
Change to netincome -305.00000M -176.00000M 155.54M 81.44M 73.46M
Capital expenditures 400.00M 284.00M 67.45M 31.55M 105.77M
Change receivables 1790.00M -1784.00000M -1385.19100M 7.22M 0.83M
Cash flows other operating -5849.00000M 2294.00M 3602.52M 16.73M -2.86900M
Exchange rate changes - - - - -
Cash and cash equivalents changes -3643.00000M 4224.00M 2388.24M -422.79200M 523.50M
Change in working capital -3455.00000M 990.00M 2577.05M -53.66400M -42.58300M
Stock based compensation 226.00M 142.00M 93.02M 81.12M 72.56M
Other non cash items 59.00M 372.00M 62.29M -3.42600M -0.97500M
Free cash flow 4581.00M 13336.00M 1959.52M -490.52200M -436.63100M

Fundamentals

  • Previous Close 108.85
  • Market Cap36180.04M
  • Volume1518074
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-2166.00013M
  • Revenue TTM9121.00M
  • Revenue Per Share TTM23.78
  • Gross Profit TTM 10552.00M
  • Diluted EPS TTM-9.23

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MRNA
Moderna Inc		 -3.6 3.31% 105.25 - 32.47 3.60 2.44 2.94 -14.7274
NVO
Novo Nordisk A/S		 -1.14 0.90% 125.02 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -3.7 2.92% 123.10 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -1.815 0.45% 398.94 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd		 -0.55 0.61% 89.55 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

View All

Profile

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a strategic partnership with Caris Life Sciences to advance mRNA-Based oncology therapeutics. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Moderna Inc

200 Technology Square, Cambridge, MA, United States, 02139

Key Executives

Name Title Year Born
Dr. Noubar B. Afeyan Ph.D. Co-Founder, Independent Non Exec. Chairman & Member of Technology Advisory Board 1963
Mr. Stephane Bancel CEO & Director 1973
Dr. Stephen Hoge M.D. Pres 1976
Ms. Shannon Thyme Klinger Chief Legal Officer & Corp. Sec. 1971
Mr. Juan Andres Pres of Strategic Partnerships & Enterprise Expansion 1965
Mr. James M. Mock Chief Financial Officer 1977
Dr. Jerh Collins Ph.D. Chief Technical Operations & Quality Officer NA
Dr. John V. W. Reynders Ph.D. Chief Information Officer NA
Dr. Melissa J. Moore Ph.D. Chief Scientific Officer & Member of Scientific Advisory Board NA
Ms. Lavina Talukdar CFA Sr. VP & Head of Investor Relations NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).